Tislelizumab, an anti-PD-1 antibody, was specifically engineered to minimize FcɣR macrophages binding to abrogate antibody-dependent phagocytosis. Compared with chemotherapy alone, tislelizumab plus chemotherapy may improve clinical outcomes in patients with advanced nonsquamous non-small cell lung cancer (nsq-NSCLC).
In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival and pathological complete response (primary endpoints; modified ITT [mITT] population,…
Most of the published data with trastuzumab deruxtecan (T-DXd) derive from clinical trials with selected populations and little representation of US patients. Limited real-world data…
Lung cancer (LC) incidence and mortality have changed significantly over the past few decades, yet the disease remains the leading cause of cancer-related deaths worldwide.…
Sugemalimab with chemotherapy showed a superior long-term overall survival benefit compared with placebo with chemotherapy, as a first-line treatment for patients with NSCLC with no…
Invasive mucinous adenocarcinoma (IMA) is a type of primary lung adenocarcinoma characterized by tumor cells that exhibit a goblet or columnar cell morphology and contain…
Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of PD-(L)1 inhibitors by inhibiting protumor inflammation.
The PHAROS primary analysis showed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report…
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard…
Microabstract: Osimertinib showed PFS of 20.1 months and OS of 42.0 months in EGFRm+ NSCLC, comparable to those of the FLAURA trial. Adverse events included…
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard…
